Agile Therapeutics, Inc. (AGRX) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in a research note issued to investors on Monday morning. HC Wainwright currently has a $10.00 target price on the specialty pharmaceutical company’s stock.
AGRX has been the topic of several other reports. Noble Financial reiterated a buy rating on shares of Agile Therapeutics in a research note on Wednesday, June 14th. ValuEngine raised Agile Therapeutics from a strong sell rating to a sell rating in a research note on Saturday, July 8th. Royal Bank Of Canada set a $8.00 target price on Agile Therapeutics and gave the stock a buy rating in a research note on Sunday, July 16th. Janney Montgomery Scott restated a buy rating and set a $15.00 price target on shares of Agile Therapeutics in a report on Friday, July 21st. Finally, Cantor Fitzgerald restated an overweight rating and set a $8.00 price target on shares of Agile Therapeutics in a report on Thursday, September 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $8.92.
Agile Therapeutics (NASDAQ AGRX) opened at 4.86 on Monday. The stock’s market capitalization is $140.00 million. Agile Therapeutics has a 1-year low of $1.82 and a 1-year high of $7.95. The company’s 50 day moving average is $3.64 and its 200-day moving average is $3.61.
Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the firm posted ($0.29) earnings per share. Analysts forecast that Agile Therapeutics will post ($1.01) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/03/agile-therapeutics-inc-agrx-receives-buy-rating-from-hc-wainwright.html.
In other news, Chairman Alfred Altomari bought 10,000 shares of the stock in a transaction that occurred on Friday, August 25th. The stock was purchased at an average price of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the purchase, the chairman now owns 161,587 shares in the company, valued at approximately $539,700.58. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.50% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Franklin Resources Inc. raised its stake in Agile Therapeutics by 39.2% in the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after buying an additional 780,578 shares in the last quarter. Royce & Associates LP lifted its holdings in Agile Therapeutics by 206.1% during the 1st quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock worth $3,165,000 after buying an additional 665,000 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in Agile Therapeutics during the 2nd quarter worth about $309,000. Dimensional Fund Advisors LP lifted its holdings in Agile Therapeutics by 604.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock worth $359,000 after buying an additional 82,213 shares during the last quarter. Finally, LMR Partners LLP purchased a new stake in Agile Therapeutics during the 2nd quarter worth about $211,000. 67.59% of the stock is currently owned by hedge funds and other institutional investors.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.